Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO · Mar 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called semaglutide on older adults who are managing conditions like diabetes or prediabetes and who are also overweight or obese. The researchers want to understand how this medication might improve physical abilities, change body composition (like muscle and fat levels), and influence signs of aging in people over 65 years old. Semaglutide is already approved for helping people lower their blood sugar and manage their weight, but this study will look at its broader effects on health in older adults.

To join this trial, participants need to be at least 65 years old, have a body mass index (BMI) of 27 or higher, and live independently, meaning they are not in a nursing home or assisted living. However, individuals with heart disease, liver disease, or who smoke are not eligible to participate. Those involved can expect to take the medication and provide information about their health over time, helping researchers learn more about how semaglutide can support healthy aging and improve quality of life for older adults.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Older than 65
• • Have prediabetes or diabetes
• • BMI ≥ 27.0 kg/m2
• • Living independently (not in assisted living or nursing home)
• Exclusion Criteria:
• • Have heart disease
• • Have liver disease
• • Smoke